David Beran and colleagues argue that the GLP-1 receptor agonists might not have been appropriate for addition to the 2025 WHO Essential Medicines List (EML) for three reasons.e First, the authors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results